Unia Europejska - polski - EMA (European Medicines Agency)

intervet international b.v. - Świńska цирковирус typu 2 (pcv2) podjednostki antygen orf2, mycoplasma hyopneumoniae szczepu j inaktywowana - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Świń (tuczu) - dla aktywnych szczepień świń w celu zmniejszenia виремии, wiremia w płucach i tkankach limfoidalnych, zaznaczenie spowodowane przez wirusa świńskiej цирковирус typu 2 (pcv2) zakażenia i stopnia uszkodzenia płuc wywołane przez mycoplasma hyopneumoniae zakażenia. aby zmniejszyć utratę dziennego przyrostu masy ciała w okresie wykańczania w przypadku zakażeń mycoplasma hyopneumoniae i / lub pcv2 (jak zaobserwowano w badaniach terenowych).

Unia Europejska - polski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - wieprzowy - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Unia Europejska - polski - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiczne dla suidae - Świń (tuczu) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Unia Europejska - polski - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inaktywowane wirusowe i inaktywowane szczepionki bakteryjne - wieprzowy - do czynnej immunizacji świń w wieku od 3 tygodni przeciwko cirkowirusowi świń typu 2 (pcv2) w celu zmniejszenia liczby wirusów we krwi i tkankach limfoidalnych oraz wydzielania kału spowodowanego zakażeniem pcv2. do aktywnej immunizacji świń w wieku powyżej 3 tygodni przeciwko mycoplasma hyopneumoniae w celu zmniejszenia zmian w płucach spowodowanych zakażeniem m. hyopneumoniae.